Starcoin Extends Convertible Bond Deadline and Delays Key Shareholder Circular

Innovative Pharmaceutical Biotech ( (HK:0399) ) just unveiled an announcement.

Starcoin Group Limited has agreed with Extrawell Pharmaceutical Holdings Limited to extend the long stop date for fulfilling conditions under the fourth deed of amendment relating to its outstanding convertible bonds from 31 March 2026 to 30 June 2026, or a later mutually agreed date. All other terms of the amendment remain unchanged, suggesting the parties are committed to completing the revised bond arrangements despite needing more time for procedural or regulatory conditions.

The company has also delayed the expected despatch date of a shareholder circular that will detail the fourth deed of amendment and convene a special general meeting, pushing the deadline from on or before 28 February 2026 to on or before 29 May 2026. Starcoin has advised shareholders and potential investors to exercise caution when dealing in its securities, underscoring the uncertainty around the timing and outcome of the proposed bond amendments and associated approvals.

The most recent analyst rating on (HK:0399) stock is a Hold with a HK$0.18 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.

More about Innovative Pharmaceutical Biotech

Starcoin Group Limited, incorporated in the Cayman Islands and continued in Bermuda with limited liability, is listed on the Hong Kong Stock Exchange under stock code 399. The company operates through a structure that includes subsidiaries and has issued convertible bonds to Extrawell Pharmaceutical Holdings Limited, indicating financing activities tied to capital market instruments.

Average Trading Volume: 26,957,435

Technical Sentiment Signal: Sell

Current Market Cap: HK$387.8M

For a thorough assessment of 0399 stock, go to TipRanks’ Stock Analysis page.